These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 38530703)

  • 41. Novel structural insights into class I and II histone deacetylases.
    Ficner R
    Curr Top Med Chem; 2009; 9(3):235-40. PubMed ID: 19355988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
    Kollar J; Frecer V
    J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
    Ru J; Wang Y; Li Z; Wang J; Ren C; Zhang J
    Eur J Med Chem; 2023 Dec; 261():115800. PubMed ID: 37708798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
    Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
    Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
    Hai Y; Christianson DW
    Nat Chem Biol; 2016 Sep; 12(9):741-7. PubMed ID: 27454933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
    Jha S; Kim JH; Kim M; Nguyen AH; Ali KH; Gupta SK; Park SY; Ha E; Seo YH
    Eur J Med Chem; 2024 Feb; 265():116057. PubMed ID: 38142511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Explorative study on isoform-selective histone deacetylase inhibitors.
    Suzuki T
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.
    Bassett SA; Barnett MP
    Nutrients; 2014 Oct; 6(10):4273-301. PubMed ID: 25322459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone deacetylases: structural determinants of inhibitor selectivity.
    Micelli C; Rastelli G
    Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of histone deacetylases in bone development and skeletal disorders.
    Wang JS; Yoon SH; Wein MN
    Bone; 2021 Feb; 143():115606. PubMed ID: 32829038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-sirtuin histone deacetylases in the control of cardiac aging.
    Ferguson BS; McKinsey TA
    J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of HDACs in normal and malignant hematopoiesis.
    Wang P; Wang Z; Liu J
    Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
    El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
    Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zinc binding groups for histone deacetylase inhibitors.
    Zhang L; Zhang J; Jiang Q; Zhang L; Song W
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):714-721. PubMed ID: 29616828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
    Kee HJ; Kim I; Jeong MH
    Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
    Simões-Pires CA; Bertrand P; Cuendet M
    Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.